HealthUS drug agency approves breakthrough pancreatic cancer treatment
The US Food and Drug Administration has approved daraxonrasib, sold as Rasonque, for pancreatic cancer. In a 500-patient late-stage trial, average survival was 13.2 months for people taking the daily pill, compared with 6.6 months for chemotherapy. The drug targets mutated KRAS, which drives tumour growth.
B
BBC News★★★☆☆2026-08-26 22:02Original
US drug agency approves breakthrough pancreatic cancer treatment
Health